Tesla, Inc. (NASDAQ:TSLA - Get Free Report) traded down 3.2% during mid-day trading on Friday . The stock traded as low as $364.46 and last traded at $367.96. 77,341,407 shares were traded during mid-day trading, an increase of 26% from the average session volume of 61,245,555 shares. The stock had previously closed at $380.30. Get Tesla alerts: Sign Up Tesla News Summary Here are the key news sto...
Tesla, Inc. (NASDAQ:TSLA - Get Free Report) traded down 3.2% during mid-day trading on Friday . The stock traded as low as $364.46 and last traded at $367.96. 77,341,407 shares were traded during mid-day trading, an increase of 26% from the average session volume of 61,245,555 shares. The stock had previously closed at $380.30. Get Tesla alerts: Sign Up Tesla News Summary Here are the key news stories impacting Tesla this week: Analyst Ratings Changes A number of equities research analysts have issued reports on TSLA shares. Wedbush reaffirmed an "outperform" rating and issued a $600.00 price objective on shares of Tesla in a research report on Thursday, January 29th. Canaccord Genuity Group set a $520.00 price objective on Tesla in a report on Thursday, January 29th. Stifel Nicolaus set a $508.00 price target on shares of Tesla in a research report on Thursday, January 29th. Morgan Stanley set a $415.00 price objective on Tesla and gave the company an "equal weight" rating in a research note on Thursday, January 29th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Tesla in a research note on Thursday, January 29th. Nineteen investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and nine have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $406.84. Get Our Latest Research Report on Tesla Tesla Price Performance The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.77 and a current ratio of 2.16. The business has a 50-day simple moving average of $416.30 and a 200 day simple moving average of $426.27. The firm has a market cap of $1.38 trillion, a P/E ratio of 340.70, a price-to-earnings-growth ratio of 11.61 and a beta of 1.89. Tesla (NASDAQ:TSLA - Get Free Report) last posted its earnings results on Wednesday, January 28th. The electric vehicle producer reported $0.50 earnings per shar...
Sio Capital Management disclosed a new position in Organon (OGN 3.91%) on February 17, 2026, acquiring 3,421,765 shares worth $24.53 million at quarter’s end. What happened According to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Sio Capital Management established a new position in Organon (OGN 3.91%), purchasing 3,421,765 shares. The reported position value ...
Sio Capital Management disclosed a new position in Organon (OGN 3.91%) on February 17, 2026, acquiring 3,421,765 shares worth $24.53 million at quarter’s end. What happened According to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Sio Capital Management established a new position in Organon (OGN 3.91%), purchasing 3,421,765 shares. The reported position value at quarter-end increased by $24.53 million as a result of the purchase. What else to know This is a new position for the fund, representing roughly 4% of 13F reportable assets under management as of December 31, 2025. Top holdings after the filing: NASDAQ:CELC: $47.58 million (7.9% of AUM) NYSE:CI: $47.40 million (7.9% of AUM) NASDAQ:SNY: $47.09 million (7.8% of AUM) NYSE:MMS: $43.19 million (7.2% of AUM) NYSE:ZBH: $34.68 million (5.7% of AUM) As of Friday, shares of Organon were priced at $6.03, down about 61% over the past year and well underperforming the S&P 500’s roughly 16% gain in the same period. Company overview Metric Value Revenue (TTM) $6.22 billion Net Income (TTM) $187.00 million Dividend Yield 1.3% Price (as of Friday) $6.03 Company snapshot Organon offers a diversified portfolio of prescription therapies, including women's health products (contraception and fertility), biosimilars in immunology and oncology, cardiovascular, respiratory, dermatology, bone health, pain management, and urology treatments. It generates revenue through the development, manufacturing, and sale of branded and biosimilar pharmaceuticals, with a focus on both established and specialty therapeutic areas. The firm serves drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers across the United States and international markets. Organon operates as a global healthcare company with a strategic emphasis on women's health and biosimilar pharmaceuticals. The company leverages a broad portfolio of established brands and specialty products to address diver...
Pimco Portfolio Manager David Forgash discusses the recent parallel increase in Treasury yields across the curve, highlighting underlying concerns about general funding conditions. Speaking on "Bloomberg The Close," Forgash notes that while the short end of the curve reflects market expectations of rate cuts, the simultaneous rise in longer-term yields indicates broader market stress. (Source: Blo...
Pimco Portfolio Manager David Forgash discusses the recent parallel increase in Treasury yields across the curve, highlighting underlying concerns about general funding conditions. Speaking on "Bloomberg The Close," Forgash notes that while the short end of the curve reflects market expectations of rate cuts, the simultaneous rise in longer-term yields indicates broader market stress. (Source: Bloomberg)
monsitj/iStock via Getty Images Gold futures fell for the seventh time in eight sessions on Friday, concluding a week that saw the metal's largest-ever single-week dollar decline and the biggest percentage slide in nearly 15 years. Gold extended losses after-hours while the dollar strengthened following reports that the U.S. will deploy more troops in the Middle East, adding to concerns over hig...
monsitj/iStock via Getty Images Gold futures fell for the seventh time in eight sessions on Friday, concluding a week that saw the metal's largest-ever single-week dollar decline and the biggest percentage slide in nearly 15 years. Gold extended losses after-hours while the dollar strengthened following reports that the U.S. will deploy more troops in the Middle East, adding to concerns over higher oil prices, inflation, and the potential for higher interest rates. Investors are continuing to shift money to other assets, despite gold's reputation as a safe-haven asset, which would typically make it an attractive place to park money during times of crisis such as the Iran war, Kieran Tompkins of Capital Economics said in a note. Gold is down 10% since the war began, and "while that is partly because U.S. real yields have risen sharply, it is also because gold has behaved increasingly like a risky asset over the past year or so," Tompkins wrote, forecasting gold to fall to $3,500/oz by year-end 2026. Despite gold's recent troubles, many analysts are still thinking positive in the longer term, including John Caruso of RJO Futures, who said in a note that "we've got significant signs of a labor slowdown, high energy costs, a no longer accommodative Fed, and persistent uncertainty around the [Middle East] war operations." Front-month Comex gold ( XAUUSD:CUR ) for March delivery fell $482.10, or 9.5%, this week to $4,570.40/oz, its largest one-week dollar decline on record based on data back to 1975 and biggest one-week percentage drop since the week ending September 23, 2011. Front-month Comex silver ( XAGUSD:CUR ) for March delivery plunged $11.554, or 14.3%, this week to $69.360/oz, its lowest settlement value since December 22, 2025. On Friday, front-month gold and silver fell by 0.6% and 2.2%, respectively; gold is still up for the full year by 5.6% while silver has turned negative, down 1.1% YTD. ETFs: ( GLD ), ( GDX ), ( GDXJ ), ( IAU ), ( NUGT ), ( PHYS ), ( GL...
JPMorgan Wealth Management CEO Kristin Lemkau discusses a new initiative designed to help support professional athletes in managing their finances, from high school all the way through retirement. She talks with Katie Greifeld and Romaine Bostick on "the Close." (Source: Bloomberg)
JPMorgan Wealth Management CEO Kristin Lemkau discusses a new initiative designed to help support professional athletes in managing their finances, from high school all the way through retirement. She talks with Katie Greifeld and Romaine Bostick on "the Close." (Source: Bloomberg)
Bjoern Wylezich/iStock Editorial via Getty Images Note: I have covered Diana Shipping Inc. or "Diana Shipping" ( DSX , DSX.PR.B , DSX.WS ) previously, so investors should view this as an update to my earlier articles on the company. Please note also that Diana Shipping, Genco Shipping & Trading ( GNK ) and Star Bulk Carriers ( SBLK ) are part of our coverage universe at Value Investor's Edge . Ref...
Bjoern Wylezich/iStock Editorial via Getty Images Note: I have covered Diana Shipping Inc. or "Diana Shipping" ( DSX , DSX.PR.B , DSX.WS ) previously, so investors should view this as an update to my earlier articles on the company. Please note also that Diana Shipping, Genco Shipping & Trading ( GNK ) and Star Bulk Carriers ( SBLK ) are part of our coverage universe at Value Investor's Edge . Reflecting On A Bad Call Eighteen months ago, I upgraded shares of leading dry bulk shipper Diana Shipping from " Hold " to " Buy " due to a number of factors: improvements in the dry bulk shipping market. deeply discounted valuation. expectations for the company's generous quarterly dividend to remain safe for the time being. Unfortunately, this turned out to be disastrous call, as the company reduced the quarterly dividend by 87% just two months after my article was published. While this was partially offset by a generous self-tender offer , mediocre market conditions and the Trump Tariffs shock resulted in the stock price dropping by more than 40% until April 2025. While shares have recovered all losses in recent quarters, Diana Shipping has underperformed peers quite meaningfully: Barchart.com Disappointing Fourth Quarter Results Last month, the company reported another set of disappointing quarterly results with both revenues and profitability falling short of expectations . Company Press Releases While Diana Shipping's conservative chartering approach results in rather stable average daily time charter equivalent ("TCE") rates, increased operating expenses and the sale of some older vessels have negatively impacted core earnings and cash flows in recent quarters. Company Presentation In fact, fourth quarter operating cash flow of $7.3 million represented a new multi-year low for the company. Diana Shipping ended the quarter with $122.2 million in cash , cash equivalents and liquid investments as well as $636.1 million in debt. Proposed Acquisition Of Genco Shipping & Tra...
EJ_Rodriquez/iStock via Getty Images Co-authored by Relative Value. Overview With this, we continue our series of articles dedicated to covering the newly listed fixed-income securities on the exchange. This time, our attention will be focused on First Horizon Corporation's ( FHN ) recent addition - the 6.75% Depositary Shares Non-Cumulative Preferred Stock, Series H ( FHN.PR.H ). As usual for thi...
EJ_Rodriquez/iStock via Getty Images Co-authored by Relative Value. Overview With this, we continue our series of articles dedicated to covering the newly listed fixed-income securities on the exchange. This time, our attention will be focused on First Horizon Corporation's ( FHN ) recent addition - the 6.75% Depositary Shares Non-Cumulative Preferred Stock, Series H ( FHN.PR.H ). As usual for this type of IPO analysis, we'll begin by going through the issuer's fundamentals to figure out whether we want exposure to its preferred equity in the first place. Once this is done, we'll continue with the same issuer and sector's peer comparison to assess the investment qualities of FHN-H in a relative value analysis. The New Issue The prospectus contains all relevant information regarding the new preferred stock. Here, we will focus on only the metrics that are most important for our analysis. FHN-H description (QuantumOnline) FHN-H pays a 6.75% annual non-cumulative dividend in $0.4219 quarterly distributions. Dividends on the new preferred shares will accrue from March 12, 2026, starting distributions on July 10, 2026. This means that the first dividend payment will be irregular in size and amount to approximately $0.5531. The preferred distributions are eligible for the preferential income tax rate. First Horizon's gross proceeds from the new security are $400 million, from a total of 16 million depositary shares issued with a liquidation preference of $25 each. The new preferred stock issue received a credit score of Ba2 from Moody's and BB from Fitch: First Horizon's credit scores (firsthorizon.com) FHN-H has no stated maturity date and may be subject to early redemption by First Horizon on or after April 10, 2031. As the issue was recently listed, its price chart looks like this: FHN-H price chart (TradingView) Currently, FHN-H is priced at $24.68 with a current yield of 6.84%, and the yield to call is determined to be 7.27% using the XIRR calculation: FHN-H YTC calc...
The dollar index (DXY00) on Friday rose by +0.42%. The dollar moved higher on Friday as weakness in stocks boosted some liquidity demand for the dollar. Also, the ongoing war in Iran has boosted demand for the dollar as a safe haven. In addition, higher T-note yields on Friday strengthened the dollar’s interest rate differentials. The dollar also has carryover support from Wednesday, when Fed Chai...
The dollar index (DXY00) on Friday rose by +0.42%. The dollar moved higher on Friday as weakness in stocks boosted some liquidity demand for the dollar. Also, the ongoing war in Iran has boosted demand for the dollar as a safe haven. In addition, higher T-note yields on Friday strengthened the dollar’s interest rate differentials. The dollar also has carryover support from Wednesday, when Fed Chair Powell said there will be no Fed rate cut unless there is progress on inflation. Swaps markets are discounting the odds at 12% for a +25 bp rate hike at the April 28-29 FOMC meeting. Join 200K+ Subscribers: The dollar continues to be undercut by a poor outlook for interest rate differentials, with the FOMC expected to cut interest rates by at least -25 bp in 2026, while the BOJ and ECB are expected to raise rates by at least +25 bp in 2026. EUR/USD (^EURUSD) on Friday fell by -0.31%. The euro was under pressure on Friday from a stronger dollar. Also, Friday’s news that showed German Feb producer prices posted their biggest decline in 1.75 years is dovish for ECB policy and negative for the euro. The euro remained lower after crude oil prices rose more than +2%, a negative factor for the Eurozone economy, as Europe imports most of its energy needs. German Feb PPI fell -3.3% y/y, weaker than expectations of -2.7% y/y and the biggest decline in 1.75 years. Hawkish comments on Friday from ECB Governing Council member and Bundesbank President Joachim Nagel were supportive of the euro when he said the ECB may need to consider raising interest rates as soon as next month if price pressures build further due to the Iran war. Swaps are discounting a 80% chance of a +25 bp rate hike by the ECB at the April 30 policy meeting. USD/JPY (^USDJPY) on Friday rose by +1.02%. The yen fell sharply on Friday amid strength in the dollar and higher T-note yields. The yen added to its losses on Friday after crude oil prices surged by more than +2%, a bearish factor for Japan’s economy, which im...
What 122 Universal Basic Income Experiments Actually Show Authroed by Vance Ginn via the Daily Economy , Artificial intelligence has become the latest excuse for reviving one of the oldest bad ideas in economic policy: a universal basic income. Recent pieces in Newsweek , the LSE Business Review , and Fortune have all helped push the idea that AI may soon wipe out so many jobs that Washington will...
What 122 Universal Basic Income Experiments Actually Show Authroed by Vance Ginn via the Daily Economy , Artificial intelligence has become the latest excuse for reviving one of the oldest bad ideas in economic policy: a universal basic income. Recent pieces in Newsweek , the LSE Business Review , and Fortune have all helped push the idea that AI may soon wipe out so many jobs that Washington will need to send everyone a check. Image Credit: Shutterstock That makes for a catchy headline. It also makes for terrible economics. The right question is not whether AI will disrupt work. Of course it will. The right question is this: after more than 100 local guaranteed-income experiments, what have we actually learned? The answer is much less flattering to UBI than its promoters would like. What 122 UBI-Style Pilots Show A new AEI working paper by Kevin Corinth and Hannah Mayhew gives the best recent overview of the evidence. Per their study, there were 122 guaranteed basic income pilots across 33 states and the District of Columbia between 2017 and 2025 . Those pilots allocated about $481.4 million in transfers to 40,921 recipients, with 61,664 total participants including control groups. The average recipient got about $11,765, the average pilot lasted 18.4 months, and the average monthly payment was $616. That sounds like a mountain of evidence. It is not. Of those 122 pilots, only 52 had published outcomes. Only 35 used randomized designs. Only 30 reported employment outcomes. So the case for UBI is not being built on some giant pile of clear, clean evidence. It is being built on a much smaller stack of studies, many of them weak, limited, or badly timed. And here is the kicker. Among the 30 randomized pilots with published employment results , the average effect was a 0.8 percentage-point increase in employment. UBI fans will rush to wave that around. They should slow down. AEI shows that the bigger and more credible studies tell a very different story . Among the fou...
tupungato Pfizer ( PFE ) is recommending that its shareholders reject a mini-tender offer from Tutanota offering to purchase up to 1M shares at $32/share. The expiration date for the offer is 5p ET on April 13. Pfizer noted that the offer is contingent on the share price closing above $32 on the last trading day before the offer expires. " This means that unless this condition is waived by Tutanot...
tupungato Pfizer ( PFE ) is recommending that its shareholders reject a mini-tender offer from Tutanota offering to purchase up to 1M shares at $32/share. The expiration date for the offer is 5p ET on April 13. Pfizer noted that the offer is contingent on the share price closing above $32 on the last trading day before the offer expires. " This means that unless this condition is waived by Tutanota, Pfizer shareholders who tender their shares in the offer will receive a below-market price," the company noted in a news release . Pfizer shares closed Friday at $26.97. More on Pfizer Pfizer: I'm Still Expecting A Massive Rebound Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation Pfizer: Cheap For A Reason Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication TrumpRx drug prices aren't the lowest as president claims - report
Paying attention to what CEOs say during earnings calls is something that investors should do for all their stock picks, but especially when it comes to companies that operate in rapidly shifting fields such as artificial intelligence (AI). One of the emerging players on the scene is Broadcom (AVGO 2.99%), as its custom AI chips offer a viable alternative to graphics processing units (GPUs) from N...
Paying attention to what CEOs say during earnings calls is something that investors should do for all their stock picks, but especially when it comes to companies that operate in rapidly shifting fields such as artificial intelligence (AI). One of the emerging players on the scene is Broadcom (AVGO 2.99%), as its custom AI chips offer a viable alternative to graphics processing units (GPUs) from Nvidia (NVDA 3.17%) in some applications. Broadcom CEO Hock Tan recently made some comments regarding the outlook for this business that investors will want to be aware of. If he's right, the stock is a screaming buy right now. Broadcom expects monster growth from its custom AI chip business Broadcom's custom AI chip business operates differently from most others. Instead of offering general-purpose processors that are marketed to every company, it partners with individual hyperscalers to design application-specific integrated chips (ASICs) that are tailored to handle precisely the sorts of AI workloads that the buyer expects them to face. This gives them a powerful chip that is more efficient and cost-effective in those particular applications, at the cost of flexibility. With every hyperscaler looking for ways to add computing power while minimizing costs, Broadcom's solution is an attractive option to complement their GPU clusters. Expand NASDAQ : AVGO Broadcom Today's Change ( -2.99 %) $ -9.57 Current Price $ 310.27 Key Data Points Market Cap $1.5T Day's Range $ 309.93 - $ 321.50 52wk Range $ 138.10 - $ 414.61 Volume 1M Avg Vol 26M Gross Margin 64.96 % Dividend Yield 0.76 % Demand for these chips is soaring. During Broadcom's fiscal 2026 first quarter, which ended Feb. 1, its AI semiconductor revenue totaled $8.4 billion, up 106% year over year. Custom AI chips are a division within that business unit, and that segment's revenue rose by 140% in Q1. However, the long-term outlook is far brighter. Tan had this to say: Reflecting the foregoing factors, our visibility in 202...
Key Points Broadcom is partnering with many hyperscalers to design AI chips to suit their specific needs. Demand for these chips is accelerating rapidly. These 10 stocks could mint the next wave of millionaires › Paying attention to what CEOs say during earnings calls is something that investors should do for all their stock picks, but especially when it comes to companies that operate in rapidly ...
Key Points Broadcom is partnering with many hyperscalers to design AI chips to suit their specific needs. Demand for these chips is accelerating rapidly. These 10 stocks could mint the next wave of millionaires › Paying attention to what CEOs say during earnings calls is something that investors should do for all their stock picks, but especially when it comes to companies that operate in rapidly shifting fields such as artificial intelligence (AI). One of the emerging players on the scene is Broadcom (NASDAQ: AVGO), as its custom AI chips offer a viable alternative to graphics processing units (GPUs) from Nvidia (NASDAQ: NVDA) in some applications. Broadcom CEO Hock Tan recently made some comments regarding the outlook for this business that investors will want to be aware of. If he's right, the stock is a screaming buy right now. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Broadcom expects monster growth from its custom AI chip business Broadcom's custom AI chip business operates differently from most others. Instead of offering general-purpose processors that are marketed to every company, it partners with individual hyperscalers to design application-specific integrated chips (ASICs) that are tailored to handle precisely the sorts of AI workloads that the buyer expects them to face. This gives them a powerful chip that is more efficient and cost-effective in those particular applications, at the cost of flexibility. With every hyperscaler looking for ways to add computing power while minimizing costs, Broadcom's solution is an attractive option to complement their GPU clusters. Demand for these chips is soaring. During Broadcom's fiscal 2026 first quarter, which ended Feb. 1, its AI semiconductor revenue totaled $8.4 billion, up 106% year over year. Custom AI chips are a division within th...
00:00 Speaker A We're calling it Market Madness, pitting 32 companies against one another in a tournament style or a bracket style tournament, I should say. Uh Julie Heman earlier today kicked off the competition, taking on the right side, unnamed. We not brand this side. We'll call it the right side of the bracket. Uh we saw McDonald's taking down Disney. 00:20 Speaker A Interestingly, Delta adva...
00:00 Speaker A We're calling it Market Madness, pitting 32 companies against one another in a tournament style or a bracket style tournament, I should say. Uh Julie Heman earlier today kicked off the competition, taking on the right side, unnamed. We not brand this side. We'll call it the right side of the bracket. Uh we saw McDonald's taking down Disney. 00:20 Speaker A Interestingly, Delta advancing over Apple. Love to talk more about that one. Maybe we'll we'll revisit that one uh next week. We're going to do the left side. We got a lot to get through. We got eight matchups. Brian Mulberry is joining us now. He is Zach's Investment Management's chief market strategist. Um so Brian, we got a bunch to get through. There's a couple of these that you highlighted. So we'll run through the first one quickly. 00:43 Speaker A Top left here, Robin Hood taking on United Health. You take Robin Hood as the winner. What's my elevator picture? 00:51 Brian Mulberry The elevator pitch here is that Robin Hood still has strong growth in front of it. We're looking at 21% earnings growth over the next several years, whereas UNH really has some headwinds from a regulatory perspective, which is really even hard to pin down what their EPS growth is going to look like in the next couple of years. So just a clear winner there in our view. 01:07 Speaker A All right, a match up that's a little more interesting and one we want to spend some time on. Pateer against Proctor and Gamble. In some ways I think about this as the company that sells everything in your home and the company that most people have no idea what they do. 01:21 Brian Mulberry Yeah, I think it's a fair assessment. And you know, on a year-to-date basis, Proctor Gamble is winning this and that they're still positive for the year. You know, obviously the market just ended. We're going to have the S&P down around 5 and a half 6% on a year-to-day basis. But Pateer has so much growth ahead of it. And it's really because they add...
Germanium Mining ( EMSKF ) announced on Friday a non-brokered private placement for aggregate gross proceeds of up to $1,350,000 consisting of the issuance of up to 3,125,000 units at $0.24 per unit and up to 1,875,000 common shares in the share capital of the company on a “flow-through” basis at $0.32 per FT share. Each unit will be comprised of one common share in the capital of the company and ...
Germanium Mining ( EMSKF ) announced on Friday a non-brokered private placement for aggregate gross proceeds of up to $1,350,000 consisting of the issuance of up to 3,125,000 units at $0.24 per unit and up to 1,875,000 common shares in the share capital of the company on a “flow-through” basis at $0.32 per FT share. Each unit will be comprised of one common share in the capital of the company and one common share purchase warrant. Each warrant will entitle the holder to purchase one additional common share for a period of 24 months from the issue date at an exercise price of $0.32 per warrant share. The proceeds from the sale of the FT Shares will be used by the Company to incur eligible “Canadian exploration expenses” that will qualify as “flow-through critical mineral mining expenditures” related to the company's projects in Quebec . All qualifying expenditures will be renounced in favor of the subscribers of the FT shares effective December 31, 2026. The Company intends to use the net proceeds from the units for general corporate and working capital purposes. The Company may pay a finder’s fee to arm's-length parties on the offering in accordance with the policies of the exchange. More on Germanium Mining Corp. Financial information for Germanium Mining Corp.